Home
overview
Recent advances in the understanding of the molecular biology, immunology and genetics of cancer are providing huge opportunities for the discovery of new cancer drugs. Oncologists are now able to quickly identify and synthesise a vast range of drugs to validated targets. Pharma companies are taking full advantage by investing heavily in new drug development. At present there are approximately 500 new compounds undergoing clinical trials and many more under development.

Current directions are away from cytotoxic drugs towards ones directed to specific cancer target molecules, making use of new platform technologies. In particular, scientists are turning their attention towards translational medicine and the need for innovation in biomarkers, surrogates and imaging. Moreover it is clear that innovative ideas for clinical trials are needed in order to meet the challenge of regulatory approval.

This conference will cover the developing technologies for drug discovery and development in cancer. It will also focus on the conversion of the science to the product, and the avoidance of the all-too-frequent expensive post-phase 3 withdrawal of compounds. It will appeal to directors and scientists from the big Pharma companies and the Biotech industry, and also to clinicians.

Gain an insight from leaders in the field
Prof Karol Sikora, Global Clinical Expert - Cancer, AstraZeneca
Dr Pearl Huang, Director, Oncology, GlaxoSmithKline
Dr George Blackledge, Vice President, Medical Director, Oncology, AstraZeneca
Dr Giorgio Massimini, Director, Clinical Oncology, Pharmacia
Dr Paolo Paoletti, Vice President, Medical – Oncology, ALIMTA Product Team Leader, Lilly
Dr Paul Quartey, Medical Director, Schering-Plough
Dr Juergen Hammer, Head, Bioinformatics, Genetics & Genomics, Roche
Dr Peter Traxler, Senior Scientist, Research Manager, Novartis
Dr Jonathan Allis, Vice President, Imaging Technology Group, Amersham Health
Dr Jeffrey Ulmer, Senior Director, Chiron
Dr Leonard Post, Senior Vice President, Research & Development, Onyx Pharmaceuticals
Prof Stephen Jackson, Deputy Director, Wellcome Trust/Cancer Research UK Institute
Prof Ian Judson, Professor, Cancer Pharmacology, Honourary Consultant Medical Oncologist, Institute of Cancer Research / Royal Marsden NHS Trust

Programme Highlights
TRANSLATIONAL MEDICINE: keep up to date with the latest technology
REGULATIONS: assess new ways of satisfying requirements
IMMUNE RESPONSE EXPLOITATION: review the current approaches
TARGETED DRUGS: focus on the new directions
NETWORKING: exchange ideas with leaders in the field

'The programme looks excellent', Prof Karol Sikora, Global Clinical Expert - Cancer, AstraZeneca

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Prof Karol Sikora

Prof Karol Sikora, Global Clinical Expert - Cancer, AstraZeneca

9:10 TRANSLATIONAL CANCER RESEARCH

Prof Karol Sikora

Prof Karol Sikora, Global Clinical Expert - Cancer, AstraZeneca

  • The paradigm shift in cancer drug development
  • The new order of corporate research organisation
  • Bridging the academic - industrial divide
  • Harnessing innovation in biomarkers, surrogates and imaging
  • Creating diagnostic capability to package with new therapeutics
  • Creating centres of excellence in translational research
  • 9:40 WHAT ARE THE CRITERIA?

    Dr George Blackledge

    Dr George Blackledge, Vice President, Medical Director, Oncology, AstraZeneca

  • Clinical benefits
  • Results of clinical trials
  • Tumour response rates required for regulatory approval
  • Convincing controls
  • Compassionate use programmes
  • 10:20 MEETING THE CHALLENGE OF PUBLIC POLICY

    Dr Paul Quartey

    Dr Paul Quartey, Medical Director, Schering-Plough

  • Mode of action of Caelyx® in fighting cancer
  • Patient selection for treatment
  • Importance of cost issues
  • Benefits of cost issues regarding numbers of patients eligible for treatment
  • Efficacy and tolerability factors
  • Ease of administration
  • 11:00 Morning Coffee

    11:20 NEW APPROACHES TO CLINICAL DEVELOPMENT

    Dr Giorgio Massimini

    Dr Giorgio Massimini, Director, Clinical Oncology, Pharmacia

  • Maximum tolerated dose
  • Biological effective dose
  • Accurate dose:response information
  • How significant is shrinkage / no shrinkage?
  • Reliability of tumour markers
  • Assessment of combination therapy of new drugs with traditional ones
  • 12:00 NEW ANTICANCER DRUGS

    Prof  Ian Judson

    Prof Ian Judson, Professor, Cancer Pharmacology, Honorary Consultant Medical Oncologist, Institute of Cancer Research / Royal Marsden NHS Trust

  • Preclinical aspects of new drug development – developing pharmacodynamic assays as an integral part of the preclinical package
  • Recently identified new targets
  • Development of mechanism-based clinical trials
  • Defining the Optimum Biological Dose – is this a realistic goal?
  • Impact of new targets on conventional concepts of Phase I / II trials

    Imatinib in gastrointestinal stromal tumour – lessons for future molecular targeted therapies

  • Satisfying the regulatory authorities – are phase II trials ever enough?
  • 12:40 Lunch

    14:00 HIGH-THROUGHPUT TARGET IDENTIFICATION AND ASSESSMENT

    Dr Juergen Hammer

    Dr Juergen Hammer, Head, Bioinformatics, Genetics & Genomics, Hoffmann-La Roche

  • Need for operational improvements of the target assessment process
  • Expression analysis technologies for drug discovery
  • Prioritising most likely drug candidates
  • Knowledge discovery in an integrated environment
  • Integrating traditional and in silico approaches
  • 14:40 IMAGING RESEARCH PROGRAMMES

    Dr Jonathan Allis

    Dr Jonathan Allis, Vice President, Technology, Amersham Health

  • Identifying new molecular diagnostic products
  • Acceleration of research decisions
  • Imaging technology
  • Facilitating early approval of new therapeutics
  • Application to treatment of cancer
  • Future potential for finding new and powerful diagnostic and therapeutic products
  • 15:20 Afternoon Tea

    15:40 MULTIPLE MYELOMA AND MYELOPROLIFERATIVE DISORDERS

    Dr Jerome Zeldis

    Dr Jerome Zeldis, Chief Medical Officer, Vice President, Medical Affairs, Celgene

  • Thalidomide
  • Celgene's STEPS programme
  • Multiple myeloma and myeloproliferative disorders
  • Myelofibrosis with myeloid metaplasia
  • REVIMID
  • ACTIMID

    Future directions

  • 16:20 ONCOLYTIC VIRUSES

    Dr Leonard Post

    Dr Leonard Post, Senior Vice President, Research & Development, Onyx Pharmaceuticals

  • Advantages of adenovirus as platform
  • Exploiting the abnormal p53 and RB pathways in malignant cells
  • Specificities of adenoviruses ONYX-015 and ONYX-411
  • Clinical experience : safety and efficacy
  • Armed therapeutic viruses : oncolytic adenoviruses as vectors for transgene delivery
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Jim Cassidy

    Prof Jim Cassidy, Professor, Oncology, Cancer Research UK, Medical Oncology

    9:10 GENES-TO-DRUGS

    Spiro Rombotis

    Spiro Rombotis, Chief Executive Officer, Cyclacel

  • Cell cycle biology pathways and checkpoint control
  • Mechanism-based anticancer drug design
  • CDK Inhibitors: an emerging class of anticancer Rx
  • Alternative approaches targeting cyclin inhibition
  • The Mitosis pathway and G2/M-specific drug design
  • Implications of the new paradigm for companies and investors
  • 9:40 TARGETED TREATMENTS

    Dr Paolo Paoletti

    Dr Paolo Paoletti, Vice President, Medical – Oncology, ALIMTA Product Team Leader, Lilly

  • Targeting treatment with cytotoxics
  • Have targeted treatments lived up to their expectations?
  • Development of new cytostatic targeted treatments
  • 10:20 SIGNAL TRANSDUCTION INHIBITION

    Dr Peter Traxler

    Dr Peter Traxler, Senior Scientist, Research Manager, Novartis

  • Mechanism of action at the molecular level
  • Rational design - a challenge for a medicinal chemist
  • Preclinical profile at the enzymatic, cellular and in vivo level
  • Clinical data
  • Successes and failures
  • Future challenges
  • 11:00 Morning Coffee

    11:20 DNA REPAIR: NEW TARGETS FOR CANCER THERAPY

    Prof Stephen Jackson

    Prof Stephen Jackson, Deputy Director, Wellcome Trust/Cancer Research UK Institute

  • Biochemical and genetic methods for validating drug targets
  • Detection, signalling and repair of DNA double strand breaks (DSB)
  • Targeting the homologous recombination system and the non-homologous end joining (NHEJ) systems
  • Inhibiting key enzymes in DNA DSB repair pathways
  • Enhancing the efficacy of chemotherapeutic agents and of ionising radiation therapy
  • Potential anti-cancer activity of DNA repair inhibitors
  • 12:00 POLYKETIDE DRUG CANDIDATES

    Prof Dan Santi

    Prof Dan Santi, Chairman, Chief Executive Officer, Kosan Biosciences

  • I. Manipulating the genetic instructions for making polyketides
  • II. Production and properties of Epothilone D
  • Clinical trials of epothilones
  • III. Hsp90 as a drug target
  • Geldanamycin analogs as chemo-sensitizers
  • 12:40 Lunch

    14:00 MULTIPLE ANTI-CANCER DRUGS WITH NOVEL MECHANISMS OF ACTION

    Dr Pearl Huang

    Dr Pearl Huang, Director, Oncology, GlaxoSmithKline

  • Role of mitotic kinesins in cell division
  • Transcriptional profiling demonstrating the over expression of kinesin spindle proteins (KSP) in cancer
  • Biochemical studies of KSP enzymatic inhibition
  • Breadth of anti-tumour activity
  • Absence of treatment-associated neuropathy
  • Preclinical data
  • 14:40 POXVIRUSES AS VECTORS FOR CANCER IMMUNOTHERAPY

    Dr Miles Carroll

    Dr Miles Carroll, Vice President, Immunotherapy, Oxford BioMedica

  • The poxvirus platform
  • Poxvirus based cancer vaccines in the clinic
  • 5T4: a novel tumour associated antigen
  • TroVax: pre-clinical studies
  • TroVax: clinical experience in late stage colorectal
  • TroVax: clinical development programme
  • 15:20 Afternoon Tea

    15:40 CANCER VACCINE STRATEGIES

    Dr Jeffrey Ulmer

    Dr Jeffrey Ulmer, Senior Director, Chiron

  • Review of vector platforms for therapeutic vaccines
  • Autologous vaccines
  • Recombinant vaccines
  • Naked antibodies
  • Radioactive conjugates

    Combination treatments

  • Encouraging results in early phase cancer vaccine clinical trials
  • 16:20 ANTIBODIES TO MODULATE TUMOUR IMMUNITY

    Dr Birgit Schultes

    Dr Birgit Schultes, Vice President, Research, AltaRex

  • Technology overview
  • Traditional use of monoclonal antibodies in cancer treatment
  • Unexpected discovery of therapeutic potential for low dose monoclonal antibodies
  • Mechanisms of immune activation by monoclonal antibodies via immune complex formation
  • Documented preclinical and clinical proof of principle
  • Broad therapeutic potential
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.